Foresee Pharmaceuticals Announces a Keynote Oral Presentation and Participation at the 2025 American Thoracic Society International Conference

Foresee Pharmaceuticals Announces a Keynote Oral Presentation and Participation at the 2025 American Thoracic Society International Conference News provided by Foresee Pharmaceuticals Co., Ltd. May 14, 2025, 09:52 ET Share this article Share to X Share this article Share to X TAIPEI , May 14, 2025 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576) ("Foresee") announced today that it will actively participate in and Toby Maher , M.D. , will deliver a keynote presentation titled "SyMMPonia: A Phase 2 Study of Linvemastat (FP-020) in Uncontrolled Asthma" at the Innovation Theater on May 18, 2025 . The session will highlight the design and objectives of the multinational syMMPonia Study , a pivotal clinical trial evaluating the efficacy of Linvemastat (FP-020), a novel Matrix Metalloproteinase-12 (MMP-12) inhibitor, in patients with uncontrolled asthma. Event Details: Speaker : Keynote Presentation by Toby Maher , M.D., Ph.D. Title : SyMMPonia: A Phase 2 Study of Linvemastat (FP-020) in Uncontrolled Asthma When: May 18, 2025 | 1:30 – 2:00 p.m. Pacific Standard Time Where: American Thoracic Society Innovation Theater 1, San Francisco, CA https:// ats2025 .d365.events/directory/sessions/c082fddd-5c54-47e7-866e-29b26d7eca3e Dr. Maher, a renowned expert in the pulmonary field, will present details of the syMMPonia Study , a Phase 2, randomized, double-blinded, placebo-controlled clinical trial designed to evaluate the efficacy of Linvemastat (FP-020) compared to placebo in patients with T2-high, moderate-to-severe asthma who remain partially controlled despite standard therapy with inhaled corticosteroids (ICS) and long-acting beta agonists (LABA) . The study aims to address unmet needs in asthma management by targeting MMP-12, an enzyme implicated in airway inflammation and remodeling. Attendees will gain insights into the rationale behind targeting MMP-12 in T2-high asthma and the study design, including patient selection and endpoints, and Potential implications for future asthma therapies. " Targeting MMP12 represents a paradigm shift, by addressing inflammation and remodeling, Linvemastat (FP-020) could redefine long-term outcomes for patients with poorly controlled asthma. Collaborative efforts to validate these results in the syMMPonia Phase 2 trial are essential to demonstrate statistically significant improvements in FEV1 and reductions in exacerbations alongside biomarker evidence of decreased collagen degradation. These findings could underscore the potential of Linvemastat (FP-020) to modify disease trajectories in high-risk patients, " stated Toby Maher , M.D., Ph.D., Professor of Clinical Medicine at Keck School of Medicine, of USC . " Today's progress exemplifies our mission to lead through innovation. syMMPonia trial is a testament to our resolve to tackle medicine's toughest challenges. We are initiating this Phase 2 trial and exploring partnerships in parallel to accelerate patient access worldwide, and we are excited to share our innovation with the clinical community during ATS ," stated Dr. Ben Chien , Ph.D., Chairman and CEO of Foresee Pharmaceuticals About Linvemastat (FP-020) and MMP-12 Linvemastat (FP-020) is a highly potent and selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases. Linvemastat (FP-020) is the new-generation MMP-12 inhibitor developed by Foresee following aderamastat (FP-025). It exhibits excellent pharmaceutical properties, with greater potency and similarly high selectivity compared to aderamastat (FP-025). Linvemastat (FP-020) has shown a favorable efficacy profile in multiple animal models of respiratory diseases and IBD. MMP-12 plays a role in asthma pathophysiology and is associated with disease severity. A Phase 2 allergen challenge asthma proof-of-concept study in aderamastat (FP-025) has been successfully completed. The key role of MMP-12 in disease is supported by single-nucleotide polymorphisms/genetic evidence related to inflammatory-fibrotic diseases, including asthma and COPD as well as correlative human expression data demonstrating a potential role of MMP-12 in disease severity and treatment responses in asthma, COPD, sarcoidosis, and IBD. MMP-12 is a key immune-fibrotic modulator secreted by macrophages and a key regulator of macrophage, neutrophil, and lung epithelial cell biology and is becoming increasingly recognized as a key marker of inflammatory exacerbations and fibrosis. About Foresee Pharmaceuticals Co., Ltd. Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (TPEx: 6576). Foresee's R&D efforts are focused on two key areas, namely its unique Stabilized Injectable Formulation (SIF) long-acting injectable (LAI) technology with derived drug products targeting specialty markets and secondly, its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee's product portfolio includes late and early-stage programs. CAMCEVI 42 mg, or the treatment of advanced prostate cancer, is now approved in the U.S., Canada , EU, Taiwan , Israel , and the UK and was launched in the U.S. in April 2022 . Additionally, the U.S. NDA for the 3-month version of CAMCEVI has been submitted and accepted for review with a PDUFA date of August 29, 2025 , while the EU regulatory submission for the 3-month version of CAMCEVI is still under preparation. For the second indication of CAMCEVI 6-month LAI formulation, central precocious puberty (CPP), the Casppian Phase 3 clinical study is ongoing. CAMCEVI 6-month LAI formulation is also being developed in a Phase 3 clinical trial in premenopausal breast cancer in China in collaboration with its partner. Aderamastat (FP-025), a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, has been investigated in a Phase 2 proof-of-concept study in allergic asthmatic patients. The study had positive outcomes, with future development in rare immune-fibrotic diseases. Linvemastat (FP-020), a follow-on oral MMP-12 inhibitor, has completed a Phase 1 study in healthy volunteers, with development targeted at severe asthma, COPD, and IBD. Mirivadelgat (FP-045) is a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which the Phase 2 WINDWARD study in pulmonary hypertension-interstitial lung disease (PH-ILD) patients is on-going. Building on the compelling biology of ALDH2 and translational data from several Foresee ALDH2 activators, a follow-on candidate from a new series of compounds is being selected for development in metabolic syndrome/healthy weight loss and the broader cardiovascular-renal-metabolic space. www.foreseepharma.com SOURCE Foresee Pharmaceuticals Co., Ltd. 21 % more press release views with Request a Demo × Modal title